Yingzi Medical Secures Nearly RMB 100 Million in Series B Funding Led by Sequoia Capital China with Follow-on Investment from F-Prime Capital

Recently, Yingzi Medical Technology (Hangzhou) Co., Ltd. (“Yingzi Medical”), a professional platform enterprise in the medical device sector, announced the completion of its Series B financing round, raising nearly RMB 100 million. The round was led by Sequoia Capital, with participation from existing shareholder FSD Capital. The funds raised will be used to further strengthen the company’s R&D capabilities, business expansion, medical education, marketing and promotion, and talent development.

Yingzi Medical was founded in late 2015 and is dedicated to providing comprehensive solutions and cost-effective innovative products for specialized segments of the medical industry. The company places a high priority on investment in research and development as well as intellectual property. Since its inception, it has planned its product portfolio layout and development with an international perspective. To date, the company has secured multiple national patents, been selected as an enterprise under the Hangzhou High-Tech Zone (Binjiang) “5050 Plan,” and been recognized as a High-Tech Enterprise in Hangzhou.

It is reported that Yingzi Medical will launch its first portfolio of innovative medical devices for gynecology in 2021, and initiate a national-level clinical medical education and training program centered on minimally invasive gynecological surgery. Adhering to the product innovation philosophy of serving physicians and benefiting patients, and guided by international standards of clinical practice, the company remains committed to forging ahead with determination, striving to ensure that female patients in China can conveniently and equitably benefit from innovations and advancements in medical technology.

Yang Yunxia, Managing Director at Sequoia Capital China, stated, “Women play vital roles in both society and the family. Caring for women’s health is a critical issue that cannot be overlooked by society, families, or individuals. The founding team of Yingzi Medical has been continuously dedicated to safeguarding women’s health, striving to shorten disease duration and mitigate the trauma caused by illness through innovative products and technologies. Sequoia Capital China aims to partner with the Yingzi team to provide support to the company as it advances along this broad and significant track.”

Lin Rui, Partner at F-Prime Capital, stated, “Women’s health has always been a key focus area for F-Prime Capital. We began deeply cultivating the women’s health sector in China as early as 2008 and subsequently co-founded Yingzi Medical. The founding team of Yingzi Medical possesses extensive and profound expertise in the field of women’s health. Since its establishment, the company has continuously innovated and expanded, evolving into a platform enterprise with multiple product lines developing simultaneously. By further increasing our investment in Yingzi Medical, we look forward to accelerating the development and promotion of innovative medical products, applying advanced and holistic technical solutions to address women’s health issues, and jointly contributing what we can to the advancement of women’s health in China.”

Sequoia Capital has always been committed to helping entrepreneurs build enduring, great companies, bringing its portfolio companies abundant global resources and valuable historical experience. Over the past 48 years, Sequoia Capital has invested in numerous innovative enterprises and leaders shaping industry trends. As “entrepreneurs behind entrepreneurs,” Sequoia Capital China focuses on investment opportunities in four sectors: technology/media, healthcare, consumer goods/services, and industrial technology. Over the past 15 years, Sequoia Capital China has invested in nearly 600 companies characterized by distinct technological advantages, innovative business models, and high growth potential.

Fidelity Growth Partners is a global proprietary investment firm backed by Fidelity International. Leveraging its unique capital structure, Fidelity Growth Partners deploys capital with flexibility to support innovative companies in disrupting or leading their markets, helping entrepreneurs realize their ambitions. Currently, Fidelity Growth Partners, together with affiliated funds under Fidelity International, ranks among the top ten venture capital firms globally. Our global ecosystem continuously provides portfolio companies with access to an extensive talent pool and deep local expertise, fueling their business growth. With over 20 years of venture capital experience in China, we have invested in more than 100 companies in the healthcare and technology innovation sectors. Over the past decade, we have invested nearly $6.5 billion in startups worldwide.